Cite
HARVARD Citation
Escudero-Vilaplana, V. et al. (2023). Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. Journal of medical economics. pp. 445-453. [Online].